Drug Profile
BMS 824393
Alternative Names: BMS-824393Latest Information Update: 28 Aug 2015
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Aug 2010 Phase-II clinical trials in Hepatitis C (in combination with peginterferon alfa-2a and ribavirin, in treatment naive patients) in USA (PO)